Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.89 USD | +1.43% | -1.59% | -11.42% |
Sales 2024 * | 461M 36.87B | Sales 2025 * | 549M 43.92B | Capitalization | 1.76B 141B |
---|---|---|---|---|---|
Net income 2024 * | 135M 10.81B | Net income 2025 * | 181M 14.49B | EV / Sales 2024 * | 2.81 x |
Net cash position 2024 * | 461M 36.94B | Net cash position 2025 * | 686M 54.9B | EV / Sales 2025 * | 1.95 x |
P/E ratio 2024 * |
13.2
x | P/E ratio 2025 * |
9.96
x | Employees | 167 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.79% |
Latest transcript on Catalyst Pharmaceuticals, Inc.
1 day | +1.43% | ||
1 week | -1.59% | ||
Current month | -6.59% | ||
1 month | -5.46% | ||
3 months | +4.20% | ||
6 months | +10.79% | ||
Current year | -11.42% |
Managers | Title | Age | Since |
---|---|---|---|
Patrick McEnany
FOU | Founder | 77 | 31/12/01 |
Richard Daly
CEO | Chief Executive Officer | 62 | 18/02/15 |
Michael Kalb
DFI | Director of Finance/CFO | 53 | 12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Patrick McEnany
FOU | Founder | 77 | 31/12/01 |
Donald Denkhaus
BRD | Director/Board Member | 78 | 18/02/15 |
David Tierney
BRD | Director/Board Member | 60 | 30/09/02 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
1.05% | 29 M€ | -4.33% | ||
0.32% | 27 M€ | -5.03% | - |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 14.89 | +1.43% | 772,457 |
25/04/24 | 14.68 | -2.91% | 926,397 |
24/04/24 | 15.12 | +2.65% | 942,143 |
23/04/24 | 14.73 | -2.45% | 992,474 |
22/04/24 | 15.1 | -0.20% | 1,015,778 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.42% | 1.76B | |
-4.66% | 86.13B | |
+1.32% | 39.82B | |
-19.27% | 30.42B | |
+57.86% | 25.23B | |
-16.09% | 15.35B | |
-9.14% | 11.95B | |
-17.69% | 11.6B | |
-43.00% | 11.51B | |
+5.24% | 8.71B |
- Stock Market
- Equities
- CPRX Stock